乳腺癌个人史患者BI-RADS 3类评估的频率与结局:FFDM与DBT比较
本回顾性研究纳入10,118例乳腺癌个人史(PHBC)患者的14,845次乳腺X线检查,比较FFDM与DBT对BI-RADS 3类评估的频率和恶性率。DBT组3类频率低于FFDM(5.6% vs 6.4%,p=.05),3类病变恶性率也低于FFDM(1.8% vs 5.0%,p=.04),且DBT组3类病变的PPV3低于FFDM(13.9% vs 36.1%,p=.02)。DBT组3类恶性率低于公认的2%上限,而FFDM组未达到。
要点
- PHBC患者中,DBT的BI-RADS 3类病变恶性率为1.8%,低于2%的可接受上限,FFDM为5.0%。
- DBT较FFDM有更低的3类频率(5.6% vs 6.4%)和更低的3类PPV3(13.9% vs 36.1%)。
- DBT组4类病变恶性率高于FFDM(32.0% vs 23.2%),提示DBT使3类和4类分类更准确。
关键影像表现/征象
- DBT组3类病变中肿块表现更常见(33.2% vs 23.1%,p=.003)。
- DBT组3类频率5.6%,FFDM组6.4%(p=.05)。
- DBT组3类病变恶性率1.8%,FFDM组5.0%(p=.04)。
诊断标准与关键数值
- BI-RADS 3类病变恶性率可接受上限为2%;DBT组为1.8%,FFDM组为5.0%。
- DBT组3类病变PPV3为13.9%,FFDM组为36.1%(p=.02)。
- DBT组4类病变恶性率32.0%,FFDM组23.2%(p=.03);5类病变恶性率两组无差异(100.0% vs 75.0%,p=.24)。
临床应用与阅片要点
- 对PHBC患者,使用DBT时BI-RADS 3类评估的恶性率在2%以下,可支持3类随访策略。
- FFDM下PHBC患者3类病变恶性率较高,需谨慎使用3类评估。
- DBT上3类病变更常见表现为肿块,阅片时需注意。
局限性
- 回顾性单中心研究,FFDM和DBT检查时间段不同,可能存在时间偏倚。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
BACKGROUND. Studies establishing the validity of BI-RADS category 3 excluded patients with personal history of breast cancer (PHBC). Use of category 3 in patients with PHBC may be impacted not only by this population's increased breast cancer risk, but also by adoption of digital breast tomosynthesis (DBT) over full-field digital mammography (FFDM). OBJECTIVE. The purpose of this article was to compare the frequency, outcomes, and additional characteristics of BI-RADS category 3 assessments between FFDM and DBT in patients with PHBC. METHODS. This retrospective study included 14,845 mammograms in 10,118 patients (mean age, 63 years) with PHBC who had undergone mastectomy and/or lumpectomy. Of these, 8422 examinations were performed by FFDM from October 2014 to September 2016, and 6423 examinations by FFDM with DBT from February 2017 to December 2018, after interval conversion of the center's mammography units. Information was extracted from the EHR and radiology reports. FFDM and DBT groups were compared in the entire sample and among index category 3 lesions (i.e., earliest category 3 assessment per lesion). RESULTS. The frequency of category 3 assessment was lower for DBT than FFDM (5.6% vs 6.4%; p = .05). DBT, compared with FFDM, showed a lower malignancy rate for category 3 lesions (1.8% vs 5.0%; p = .04), higher malignancy rate for category 4 lesions (32.0% vs 23.2%; p = .03), and no difference in malignancy rate for category 5 lesions (100.0% vs 75.0%; p = .24). Analysis of index category 3 lesions included 438 and 274 lesions for FFDM and DBT, respectively. For category 3 lesions, DBT, compared with FFDM, showed lower PPV3 (13.9% vs 36.1%; p = .02) and a more frequent mammographic finding of mass (33.2% vs 23.1%; p = .003). CONCLUSION. The malignancy rate for category 3 lesions in patients with PHBC was less than the accepted limit (2%) for DBT (1.8%), but not FFDM (5.0%). A lower malignancy rate for category 3 lesions but higher malignancy rate for category 4 lesions for DBT supports more appropriate application of category 3 assessment in patients with PHBC through use of DBT. CLINICAL IMPACT. These insights may help establish whether category 3 assessments in patients with PHBC are within benchmarks for early detection of second cancers and reduction of benign biopsies.
引用
- Offit LR, Chikarmane SA, Lacson RC, et al. Frequency and Outcomes of BI-RADS Category 3 Assessments in Patients With a Personal History of Breast Cancer: Full-Field Digital Mammography Versus Digital Breast Tomosynthesis. AJR Am J Roentgenol. 2023. PMID: 37095672. doi:10.2214/AJR.23.29067
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。